Alexander Campolo, DO
Adult Medicine · Newark, OHNPI 1306230255
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations.
Across 31 payments — averaging $16.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$98
- AbbVie$78
- E.r. Squibb & Sons, L.L.C.$72
- Pfizer$57
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$33
- Novo Nordisk$29
- plus $138 from 9 others
What the payments were for
- Food & beverage$505100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 6 | $98 |
| AbbVie(2 entities) | 4 | $78 |
| E.r. Squibb & Sons, L.L.C. | 4 | $72 |
| Pfizer | 4 | $57 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Novo Nordisk | 2 | $29 |
| Dexcom, Inc. | 1 | $21 |
| GSK | 1 | $19 |
| Astellas Pharma US Inc | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| AstraZeneca | 1 | $15 |
| Harmony Biosciences LLC | 1 | $13 |
| Lilly USA, LLC | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $12 |
| Amgen | 1 | $12 |
How this compares
$505 in reported general payments places this provider in the 65th percentile of 22 adult medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 204 | $220,360 |
| OzempicSemaglutide | 122 | $169,524 |
| JardianceEmpagliflozin | 100 | $136,248 |
| JanuviaSitagliptin Phosphate | 74 | $95,703 |
| TrulicityDulaglutide | 58 | $88,442 |
| MounjaroTirzepatide | 37 | $43,070 |
| SynjardyEmpagliflozin/Metformin Hcl | 42 | $35,502 |
| XareltoRivaroxaban | 36 | $31,502 |
| FarxigaDapagliflozin Propanediol | 20 | $25,112 |
| Tresiba Flextouch U-100Insulin Degludec | 31 | $21,679 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $21,036 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $19,917 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 30 | $16,792 |
| CreonLipase/Protease/Amylase | 12 | $15,901 |
| Advair HfaFluticasone Propion/Salmeterol | 21 | $14,447 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $57 | $220,360204 claims |
| Novo NordiskOzempic | $29 | $169,524122 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $13 | $131,51295 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $15 | $48,90745 claims |
| AbbVieCreon, Linzess, Synthroid | $78 | $31,982102 claims |
| GSKTrelegy Ellipta | $19 | $21,03615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 22 adult medicine providers in Ohio.
Other adult medicine in Newark
- Ramalingam SelvarajahLondon$6K
- Angela GarlandCincinnati$4K
- Farzana TausifSylvania$3K
- Olusegun OdukoyaCleveland$2K
- Thomas SchmeiserTallmadge$823
- Charles KellerLogan$526
- Malini DesaiAkron$511
- Tiffany SwainColumbus$448
- William SawyerCincinnati$443
- Malinda PowellLancaster$433
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.